Rockland, MA, April 15, 2013 – A Pennsylvania appellate court recently decided that the collaboration agreement that EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany and Pfizer Inc. entered into in July 2002 for the co-promotion of the multiple sclerosis treatment Rebif® (interferon beta-1a) extends until December 31, 2015.
EMD Serono, which developed Rebif, had contended that the collaboration should end on December 31, 2013, based on the provisions of the agreement governing extension of the term, and had filed a complaint seeking a court declaration to that end. A lower court ruled that the agreement extends through 2015 and the appellate court affirmed that decision. EMD Serono has asked the appellate court to reconsider its ruling. Unless the court grants the request on or before June 7, it will be deemed denied.
EMD Serono remains committed to the success of Rebif and its efforts to promote Rebif. The decision will have no impact on patients or supply of Rebif and does not change the company’s Rebif business plans and growth prospects in the US.
About EMD Serono
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com
About Merck KGaA
Merck KGaA of Darmstadt, Germany, is a leading pharmaceutical, chemical and life science company with total revenues of €11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 39,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck KGaA's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merckgroup.com.
Erin-Marie Beals 781-681-2850